Curated News
By: NewsRamp Editorial Staff
May 13, 2024
Lisata Therapeutics Prepares for Crucial ASCEND Trial Results in 2024
TLDR
- Lisata Therapeutics Inc anticipates pivotal Phase 2b ASCEND trial data in Q4 2024, potentially leading to provisional approval applications and partnership announcements.
- Lisata Therapeutics Inc CEO David Mazzo discusses first-quarter milestones, effective cash management, achieved regulatory milestones, and plans for expanding trials and potential partnerships.
- Lisata Therapeutics Inc's progress in oncology research and potential approval applications can lead to improved treatment options for cancer patients, making the world a better place.
- Lisata Therapeutics Inc's rapid progress in the BOLSTER trial and potential partnership announcements by year-end make the company's oncology developments interesting and impactful.
Impact - Why it Matters
Readers should care about Lisata Therapeutics' upcoming pivotal year as it could potentially lead to provisional approval applications, regulatory milestones, and early data points in the oncology field. The company's partnerships and developments may have a significant impact on the future of cancer treatment.
Summary
Lisata Therapeutics Inc (NASDAQ:LSTA) CEO David Mazzo discusses the company's pivotal year in 2024, including the anticipated Phase 2b ASCEND trial top-line data and first-quarter milestones. The company's effective cash management, regulatory milestones, and rapid progress of the BOLSTER trial are highlighted, with potential partnership announcements expected by year-end.
Source Statement
This curated news summary relied on this press release disributed by News Direct. Read the source press release here, Lisata Therapeutics Prepares for Crucial ASCEND Trial Results in 2024
